{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:32:17Z","timestamp":1783632737618,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NCI #8871"],"award-info":[{"award-number":["NCI #8871"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41416-019-0473-y","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T23:05:23Z","timestamp":1558047923000},"page":"1105-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment"],"prefix":"10.1038","volume":"120","author":[{"given":"Bora","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi K.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie S.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuhad K.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abenaa M.","family":"Brewster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H.","family":"Barcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Powel H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Booser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Moscow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Piekarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"473_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"473_CR2","unstructured":"Breast cancer by the numbers. 39, 213\u2013214 (2014). \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4005124\/"},{"key":"473_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"473_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124\u20131130 (2010).","journal-title":"J. Clin. Oncol."},{"key":"473_CR5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733\u20132743 (2006).","journal-title":"N. Engl. J. Med."},{"key":"473_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","volume":"14","author":"T Bachelot","year":"2013","unstructured":"Bachelot, T., Romieu, G., Campone, M., Dieras, V., Cropet, C., Dalenc, F. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14, 64\u201371 (2013).","journal-title":"Lancet Oncol."},{"key":"473_CR7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin, N. U., Dieras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H. J. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452\u20131459 (2009).","journal-title":"Clin. Cancer Res."},{"key":"473_CR8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","volume":"30","author":"KL Blackwell","year":"2012","unstructured":"Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585\u20132592 (2012).","journal-title":"J. Clin. Oncol."},{"key":"473_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","volume":"20","author":"FJ Esteva","year":"2002","unstructured":"Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L. et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 1800\u20131808 (2002).","journal-title":"J. Clin. Oncol."},{"key":"473_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cncr.22885","volume":"110","author":"HJ Burstein","year":"2007","unstructured":"Burstein, H. J., Keshaviah, A., Baron, A. D., Hart, R. D., Lambert-Falls, R., Marcom, P. K. et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110, 965\u2013972 (2007).","journal-title":"Cancer"},{"key":"473_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"RW Johnstone","year":"2002","unstructured":"Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287\u2013299 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"473_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10549-014-3014-7","volume":"146","author":"J Lee","year":"2014","unstructured":"Lee, J., Bartholomeusz, C., Mansour, O., Humphries, J., Hortobagyi, G. N., Ordentlich, P. et al. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 146, 259\u2013272 (2014).","journal-title":"Breast Cancer Res Treat."},{"key":"473_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2011.03.019","volume":"307","author":"X Huang","year":"2011","unstructured":"Huang, X., Wang, S., Lee, C. K., Yang, X., Liu, B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 307, 72\u201379 (2011).","journal-title":"Cancer Lett."},{"key":"473_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118\u2013145 (2007).","journal-title":"J. Clin. Oncol."},{"key":"473_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"473_CR16","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n                    \n                  . Accessed on 30 Jan 2018."},{"key":"473_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","volume":"14","author":"A Robidoux","year":"2013","unstructured":"Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E. Jr., Azar, C. A., Atkins, J. N. et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 14, 1183\u20131192 (2013).","journal-title":"Lancet Oncol."},{"key":"473_CR18","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1200\/JCO.2011.40.5241","volume":"31","author":"Z Guan","year":"2013","unstructured":"Guan, Z., Xu, B., DeSilvio, M. L., Shen, Z., Arpornwirat, W., Tong, Z. et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J. Clin. Oncol. 31, 1947\u20131953 (2013).","journal-title":"J. Clin. Oncol."},{"key":"473_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(12)70508-9","volume":"14","author":"P Goss","year":"2013","unstructured":"Goss, P., Smith, I., O\u2019Shaughnessy, J., Ejlertsen, B., Kaufmann, M., Boyle, F. et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 14, 88\u201396 (2013).","journal-title":"Lancet Oncol."},{"key":"473_CR20","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128\u20132135 (2013).","journal-title":"J. Clin. Oncol."},{"key":"473_CR21","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1535-7163.MCT-12-1167","volume":"12","author":"G Kallergi","year":"2013","unstructured":"Kallergi, G., Konstantinidis, G., Markomanolaki, H., Papadaki, M. A., Mavroudis, D., Stournaras, C. et al. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol. Cancer Ther. 12, 1886\u20131895 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"473_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2907","volume":"13","author":"M Giuliano","year":"2011","unstructured":"Giuliano, M., Giordano, A., Jackson, S., Hess, K. R., De Giorgi, U., Mego, M. et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13, R67 (2011).","journal-title":"Breast Cancer Res."},{"key":"473_CR23","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1158\/1078-0432.CCR-17-3059","volume":"24","author":"HS Rugo","year":"2018","unstructured":"Rugo, H. S., Cortes, J., Awada, A., O\u2019Shaughnessy, J., Twelves, C., Im, S. A. et al. Change in topoisomerase 1-positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol. Clin. Cancer Res. 24, 3348\u20133357 (2018).","journal-title":"Clin. Cancer Res."},{"key":"473_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","volume":"36","author":"DG Stover","year":"2018","unstructured":"Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H. et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J. Clin. Oncol. 36, 543\u2013553 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0473-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0473-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:55Z","timestamp":1684616695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0473-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0473-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by institutional review boards at The University of Texas MD Anderson Cancer Center. All enroled patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent the material to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All data generated or analysed during this study are included in this published article [and its\u00a0].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}},{"value":"This study was supported by the National Cancer Institute at the National Institutes of Health through a Cancer Therapy Evaluation Program UM1 grant [NCI #8871] and MD Anderson\u2019s Cancer Center Support Grant [P30CA016672; used the Clinical Trials Support Resource and Biostatistics Resource Group]; MD Anderson\u2019s Center for Genetics and Genomics (used the Molecular Cytogenetics Facility); and the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}